Migotanie przedsionków w 2019 r. w świetle najnowszych wytycznych północnoamerykańskich towarzystw naukowych – czy istnieje konsensus transatlantycki? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2018
Słowa kluczowe:
wytyczne, migotanie przedsionków, leczenie przeciwzakrzepowe, udar mózgu
##plugins.themes.bootstrap3.article.main##
Abstrakt
Migotanie przedsionków (AF, atrial fibrillation) to jedna z najczęstszych arytmii w codziennej praktyce klinicznej. Z powodu rosnącej średniej długości życia AF stwierdzane jest u ponad 3% osób w społeczeństwach wysoko rozwiniętych. W ciągu ostatnich kilku miesięcy opublikowano nowe zalecenia AHA/ACC/HRS (American Heart Association, American College of Cardiology/Heart Rhythm Society) i CCS (Canadian Cardiology Society). Autorzy wspomnianych dokumentów najwięcej uwagi poświęcili profilaktyce przeciwkrzepliwej w związku z zatwierdzeniem nowych leków i urządzeń, przezcewnikowej ablacji AF oraz zintegrowanemu podejściu do pacjentów ze stwierdzonym AF, w tym chorych z niewydolnością serca oraz po ostrym zespole wieńcowym.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Krzykwa , A., Setny , M., Kwiatkowska , M., & Kosior , D. A. (2018). Migotanie przedsionków w 2019 r. w świetle najnowszych wytycznych północnoamerykańskich towarzystw naukowych – czy istnieje konsensus transatlantycki?. Kardiologia W Praktyce, 12(3-4), 28-36. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1210
Numer
Dział
Dowody medyczne w kardiologii
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Kirchhof P., Benussi S., Kotecha D. et al.: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016; 37(38): 2893-2962.
2. January C.T.J., Wann L.S., Calcins H. et al.: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation; JACC 2019. https://doi.org/10.1016/j.jacc.2019.01.11.
3. Andrade J.G., Verma A., Mitchell L.B. et al.: 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can. J. Cardiol. 2018; 34(11): 1371-1392.
4. Siontis K.C., Zhang X., Eckard A. et al.: Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation 2018; 138: 1519-1529.
5. Winkelmayer W.C., Liu J., Setoguchi S. et al.: Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin. J. Am. Soc. Nephrol. 2011; 6: 2662-2668.
6. Bonde A.N., Lip G.Y.H., Kamper A.L. et al.: Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J. Am. Coll. Cardiol. 2014; 64: 2471-2482.
7. Reddy V.Y., Sievert H., Halperin J. et al.: Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014; 312: 1988-1998.
8. Boersma L.V.A., Schmidt B., Betts T.R. et al.: Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur. Heart J. 2016; 37: 2465-1474.
9. Siegal D.M., Curnutte J.T., Connolly S.J. et al.: Andexanet alfa for the reversal of factor Xa inhibitor activity. N. Engl. J. Med. 2015; 373: 2413-2424.
10. Connolly S.J., Milling T.J. Jr, Eikelboom J.W. et al.: Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N. Engl. J. Med. 2016; 375: 1131-1141.
11. Douketis J.D., Spyropoulos A.C., Kaatz S. et al.: Perioperative bridging anticoagulation in patients with atrial fibrillation. N. Engl. J. Med. 2015; 373: 823-833.
12. Lip G.Y., Laroche C., Dan G.A. et al.: A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-319.
13. Connolly S., Pogue J., Hart R. et al.: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
14. Palmerini T., Benedetto U., Bacchi-Reggiani L. et al.: Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015; 385(9985): 2371-2382. http://doi.org/10.1016/s0140-6736(15)60263-x.
15. Navarese E.P., Andreotti F., Schulze V. et al.: Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015; 350: h1618. http:/doi.org/10.1136/bmj.h1618.
16. Valgimigli M., Bueno H., Byrne H. et al.: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2018; 39(3): 213-260.
17. Cannon C.P., Bhatt D.L., Oldgren J. et al.: RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N. Engl. J. Med. 2017; 377(16): 1513-1524. http://doi.org/10.1056/NEJMoa1708454.
18. Neuman F.J., Sousa-Uva M., Ahlsson A. et al.: 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2019; 40(2): 87-165.
19. Bonaca M.P., Bhatt D.L., Steg P.G. et al.: Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur. Heart J. 2016; 37(14): 1133-1142. http://doi.org/10.1093/eurheartj/ehv531.
20. Eikelboom J.W., Connolly S.J., Bosch J. et al.: Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 2017; 377: 1319-1330.
21. Gibson C.M., Mehran R., Bode C. et al.: Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N. Engl. J. Med. 2016; 375(25): 2423-2434. http://doi.org/10.1056/NEJMoa1611594.
22. Hendriks J.M., de Wit R., Crijns H.J. et al.: Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur. Heart J. 2012; 33: 2692-2699.
2. January C.T.J., Wann L.S., Calcins H. et al.: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation; JACC 2019. https://doi.org/10.1016/j.jacc.2019.01.11.
3. Andrade J.G., Verma A., Mitchell L.B. et al.: 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can. J. Cardiol. 2018; 34(11): 1371-1392.
4. Siontis K.C., Zhang X., Eckard A. et al.: Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation 2018; 138: 1519-1529.
5. Winkelmayer W.C., Liu J., Setoguchi S. et al.: Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin. J. Am. Soc. Nephrol. 2011; 6: 2662-2668.
6. Bonde A.N., Lip G.Y.H., Kamper A.L. et al.: Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J. Am. Coll. Cardiol. 2014; 64: 2471-2482.
7. Reddy V.Y., Sievert H., Halperin J. et al.: Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014; 312: 1988-1998.
8. Boersma L.V.A., Schmidt B., Betts T.R. et al.: Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur. Heart J. 2016; 37: 2465-1474.
9. Siegal D.M., Curnutte J.T., Connolly S.J. et al.: Andexanet alfa for the reversal of factor Xa inhibitor activity. N. Engl. J. Med. 2015; 373: 2413-2424.
10. Connolly S.J., Milling T.J. Jr, Eikelboom J.W. et al.: Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N. Engl. J. Med. 2016; 375: 1131-1141.
11. Douketis J.D., Spyropoulos A.C., Kaatz S. et al.: Perioperative bridging anticoagulation in patients with atrial fibrillation. N. Engl. J. Med. 2015; 373: 823-833.
12. Lip G.Y., Laroche C., Dan G.A. et al.: A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-319.
13. Connolly S., Pogue J., Hart R. et al.: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
14. Palmerini T., Benedetto U., Bacchi-Reggiani L. et al.: Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015; 385(9985): 2371-2382. http://doi.org/10.1016/s0140-6736(15)60263-x.
15. Navarese E.P., Andreotti F., Schulze V. et al.: Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015; 350: h1618. http:/doi.org/10.1136/bmj.h1618.
16. Valgimigli M., Bueno H., Byrne H. et al.: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2018; 39(3): 213-260.
17. Cannon C.P., Bhatt D.L., Oldgren J. et al.: RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N. Engl. J. Med. 2017; 377(16): 1513-1524. http://doi.org/10.1056/NEJMoa1708454.
18. Neuman F.J., Sousa-Uva M., Ahlsson A. et al.: 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2019; 40(2): 87-165.
19. Bonaca M.P., Bhatt D.L., Steg P.G. et al.: Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur. Heart J. 2016; 37(14): 1133-1142. http://doi.org/10.1093/eurheartj/ehv531.
20. Eikelboom J.W., Connolly S.J., Bosch J. et al.: Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 2017; 377: 1319-1330.
21. Gibson C.M., Mehran R., Bode C. et al.: Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N. Engl. J. Med. 2016; 375(25): 2423-2434. http://doi.org/10.1056/NEJMoa1611594.
22. Hendriks J.M., de Wit R., Crijns H.J. et al.: Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur. Heart J. 2012; 33: 2692-2699.